90915-45-0

Basic information

• Product Name: 4(1H)-Quinazolinone, 8-methoxy-2-methyl- (9CI)
• Synonyms: 4(1H)-Quinazolinone, 8-methoxy-2-methyl- (9CI);8-Methoxy-2-Methyl-4(1H)-quinazolinone;8-Methoxy-2-Methyl-3H-quinazolin-4-one
• CAS NO: 90915-45-0
• Molecular Formula: C10H10N2O2
• Molecular Weight: 190.2
• Product Categories: Aromatics
• Mol File: 90915-45-0.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4(1H)-Quinazolinone, 8-methoxy-2-methyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4(1H)-Quinazolinone, 8-methoxy-2-methyl- (9CI)(90915-45-0)
• EPA Substance Registry System: 4(1H)-Quinazolinone, 8-methoxy-2-methyl- (9CI)(90915-45-0)

Safety Data

• Statements: 22
• Safety Statements: 36/37
• Hazardous Substances Data: 90915-45-0(Hazardous Substances Data)

Usage

Description

4(1H)-Quinazolinone, 8-methoxy-2-methyl(9CI) is a chemical compound belonging to the quinazolinone family. It is characterized by the presence of a quinazolinone core with a methyl group at the 2nd position and a methoxy group at the 8th position. 4(1H)-Quinazolinone, 8-methoxy-2-methyl (9CI) is known for its potential applications in various fields, particularly in organic synthesis.

Uses

Used in Organic Synthesis:
4(1H)-Quinazolinone, 8-methoxy-2-methyl(9CI) is used as a key intermediate in the synthesis of various organic compounds. Its unique structure allows for the formation of diverse chemical entities, making it a valuable building block in the development of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4(1H)-Quinazolinone, 8-methoxy-2-methyl(9CI) is utilized as a starting material for the synthesis of novel drug candidates. Its structural features enable the design of molecules with potential therapeutic properties, such as anticancer, antiviral, and anti-inflammatory agents.
Used in Agrochemical Industry:
4(1H)-Quinazolinone, 8-methoxy-2-methyl(9CI) also finds application in the agrochemical industry, where it serves as a precursor for the development of new pesticides and herbicides. Its ability to form a variety of chemical entities allows for the creation of compounds with improved efficacy and selectivity against target pests and weeds.

Upstream product

• 3177-80-8 2-amino-3-methoxybenzoic acid 
• 4920-80-3 3-methoxy-2-nitrobenzoic acid 
• 75-05-8 acetonitrile 
• 106782-78-9 3-methoxy-2-aminobenzamide 
• 74-88-4 methyl iodide 
• 75-36-5 acetyl chloride 
• 172462-98-5 2-N-Acetylamino-3-methoxybenzamide 
• 93-26-5 2-methoxyacetanilide 
• 51-79-6 urethane 
• 54905-94-1 8-methoxy-2-methyl-4H-benzo[d][1,3]oxazin-4-one 

Downstream Products

• 102660-84-4 2-(3,4-diethoxy-trans-styryl)-8-methoxy-3H-quinazolin-4-one 
• 101444-64-8 8-methoxy-2-trans-quinazolin-4-one 
• 101731-86-6 8-methoxy-2-(4-methoxy-trans-styryl)-3H-quinazolin-4-one 
• 90417-38-2 8-hydroxy-2-methyl-4(3H)-quinazolinone 
• 154288-17-2 4-chloro-8-methoxy-2-methylquinazoline 
• 104296-30-2 2,3-dimethyl-8-methoxyquinazolin-4-one 
• 387346-77-2 4-[3-(8-methoxy-2-methyl-4-oxo-4H-quinazolin-3-yl)-propyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 99071-94-0 8-hydroxy-2,3-dimethyl-quinazolin-4(3H)-one 
• 105459-51-6 8-hydroxy-2-ethyl-quinazolin-4(3H)-one 

Relevant articles and documents

Studies towards hypoxia-activated prodrugs of PARP inhibitors

Poly(ADP-ribose)polymerase (PARP) inhibitors (PARPi) have recently been approved for the treatment of breast and ovarian tumors with defects in homologous recombination repair (HRR). Although it has been demonstrated that PARPi also sensitize HRR competent tumors to cytotoxic chemotherapies or radiotherapy, normal cell toxicity has remained an obstacle to their use in this context. Hypoxia-activated prodrugs (HAPs) provide a means to limit exposure of normal cells to active drug, thus adding a layer of tumor selectivity. We have investigated potential HAPs of model PARPi in which we attach a bioreducible “trigger” to the amide nitrogen, thereby blocking key binding interactions. A representative example showed promise in abrogating PARPi enzymatic activity in a biochemical assay, with a ca. 160-fold higher potency of benzyl phthalazinone 4 than the corresponding model HAP 5, but these N-alkylated compounds did not release the PARPi upon one-electron reduction by radiolysis. Therefore, we extended our investigation to include NU1025, a PARPi that contains a phenol distal to the core binding motif. The resulting 2-nitroimidazolyl ether provided modest abrogation of PARPi activity with a ca. seven-fold decrease in potency, but released the PARPi efficiently upon reduction. This investigation of potential prodrug approaches for PARPi has identified a useful prodrug strategy for future exploration.

Total synthesis of penipanoid C, 2-(4-hydroxybenzyl)quinazolin-4(3H)-one and NU1025

The first total synthesis of penipanoid C and 2-(4-hydroxybenzyl)quinazolin-4(3H)-one is reported using a greener mild deep eutectic solvent mediated cyclization strategy with good overall yields. NU1025 drug is also synthesized using the similar protocol.

Methods, compounds and compositions for treating gout

This invention relates to methods of preventing, treating or lessening verity of gout by administration of PARP inhibitors.